A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT07376707 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

194

Enrollment

OTHER

Sponsor class

Conditions

CRC (Colorectal Cancer)
Melanoma (Skin Cancer)
HCC - Hepatocellular Carcinoma
NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: TGI-5

Sponsor

Hefei TG ImmunoPharma Co., Ltd.

Collaborators

[object Object]